Emergent seeking to reverse fortunes and become a major overdose treatment player
The company reported a 10% annual revenue increase to $849m between Q3 2023 and Q3 2024.
Comment & Opinion
FDA review designations: tracking 40 years of innovation
FDA’s START and CoGenT pilot programmes: Streamlining rare disease drug approvals
Interleukin inhibitors remain a strong growth driver in dermatology
JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy
Mega M&A at JP Morgan Conference 2025 — is biopharma M&A poised for a rebound?
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
“Nothing to do with geopolitics”: WuXi Biologics CEO bullish in face of Biosecure
